Tao Liang

Tao Liang

Auto-generated profile, based on publicly available information

Tao Liang

Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2024 in New England Journal of Medicine
Verified
Journal Article
Open access
CDChristine M. Durand
Christine M. Durand
AMAllan Massie
Allan Massie
SFSander Florman
Sander Florman
TLTao Liang
Tao Liang
MRMeenakshi M. Rana
Meenakshi M. Rana
DSDorry L. Segev
Dorry L. Segev
Kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ Policy Equity Act and is currently approved for research only. The Department of Health and Human Services is considering expanding the procedure to clinical practice, but data are limited to small case series that did not include donors without HIV as controls. In an observational study conducted at 26 U.S. centers, we compared transplantation of kidneys from deceased donors with HIV and donors without HIV to recipients with HIV. The primary outcome was a safety event (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic infection), assessed for noninferiority (margin for the upper bound of the 95% confidence interval, 3.00). Secondary outcomes included overall survival, survival without graft loss, rejection, infection, cancer, and HIV superinfection. We enrolled 408 transplantation candidates, of whom 198 received a kidney from a deceased donor; 99 received a kidney from a donor with HIV and 99 from a donor without HIV. The adjusted hazard ratio for the composite primary outcome was 1.00 (95% confidence interval [CI], 0.73 to 1.38), which showed noninferiority. The following secondary outcomes were similar whether the donor had HIV or not: overall survival at 1 year (94% vs. 95%) and 3 years (85% vs. 87%), survival without graft loss at 1 year (93% vs. 90%) and 3 years (84% vs. 81%), and rejection at 1 year (13% vs. 21%) and 3 years (21% vs. 24%). The incidence of serious adverse events, infections, surgical or vascular complications, and cancer was similar in the groups. The incidence of HIV breakthrough infection was higher among recipients of kidneys from donors with HIV (incidence rate ratio, 3.14; 95%, CI, 1.02 to 9.63), with one potential HIV superinfection among the 58 recipients in this group with sequence data and no persistent failures of HIV treatment. In this observational study of kidney transplantation in persons with HIV, transplantation from donors with HIV appeared to be noninferior to that from donors without HIV. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT03500315.).

19 February 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
Nitipong PermpalungNitipong Permpalung
Nitipong Permpalung
TLTao Liang
Tao Liang
SGShilpa Gopinath
Shilpa Gopinath
KBKatrina Bazemore
Katrina Bazemore
JMJoby Mathew
Joby Mathew
PSPali D. Shah
Pali D. Shah

17 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YLYongbin Li
Yongbin Li
DZDi Zhao
Di Zhao
THTakeo Horie
Takeo Horie
GCGeng Chen
Geng Chen
HBHongcun Bao
Hongcun Bao
XLXiao Liu
Xiao Liu
Significance: The lateral neural plate border (NPB) gives rise to the neural crest, one of the precursors of the peripheral nervous system (PNS) and generally considered an evolutionary innovation of the vertebrate lineage. Recently, it has been reported that a rudimentary neural crest exists in protovertebrate Ciona , but whether this is true in other invertebrates and there is conserved molecular machinery specifying the NPB lineage are unknown. We present evidence that orthologs of the NPB specification module specify lateral neural progenitor cells in several invertebrates, including worm, fly, and tunicate. We propose that an ancient lateral neuroblast gene regulatory module was coopted by chordates during the evolution of PNS progenitors.

24 March 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
WWWilliam Werbel
William Werbel
AKAndrew H. Karaba
Andrew H. Karaba
TCTeresa Po-Yu Chiang
Teresa Po-Yu Chiang
AMAllan B. Massie
Allan B. Massie
DBDiane M. Brown
Diane M. Brown
DSDorry Segev
Dorry Segev
Kidney transplant recipients (KTRs) show poorer response to SARS-CoV-2 mRNA vaccination, yet response patterns and mechanistic drivers following third doses are ill-defined. We administered third monovalent mRNA vaccines to n = 81 KTRs with negative or low-titer anti-receptor binding domain (RBD) antibody (n = 39 anti-RBDNEG; n = 42 anti-RBDLO), compared with healthy controls (HCs, n = 19), measuring anti-RBD, Omicron neutralization, spike-specific CD8+%, and SARS-CoV-2-reactive T cell receptor (TCR) repertoires. By day 30, 44% anti-RBDNEG remained seronegative; 5% KTRs developed BA.5 neutralization (vs 68% HCs, P < .001). Day 30 spike-specific CD8+% was negative in 91% KTRs (vs 20% HCs; P = .07), without correlation to anti-RBD (rs = 0.17). Day 30 SARS-CoV-2-reactive TCR repertoires were detected in 52% KTRs vs 74% HCs (P = .11). Spike-specific CD4+ TCR expansion was similar between KTRs and HCs, yet KTR CD8+ TCR depth was 7.6-fold lower (P = .001). Global negative response was seen in 7% KTRs, associated with high-dose MMF (P = .037); 44% showed global positive response. Of the KTRs, 16% experienced breakthrough infections, with 2 hospitalizations; prebreakthrough variant neutralization was poor. Absent neutralizing and CD8+ responses in KTRs indicate vulnerability to COVID-19 despite 3-dose mRNA vaccination. Lack of neutralization despite CD4+ expansion suggests B cell dysfunction and/or ineffective T cell help. Development of more effective KTR vaccine strategies is critical. (NCT04969263).

5 May 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PNPuja H Nambiar
Puja H Nambiar
TLTao Liang
Tao Liang
NLNazzarena Labo
Nazzarena Labo
JHJonathan M. Hand
Jonathan M. Hand
EBEmily A Blumberg
Emily A Blumberg
CDChristine M Durand
Christine M Durand
Background: Due to high prevalence of Kaposi sarcoma–associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+). Methods: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D–) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD. Results: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D–. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07–2.14] in recipients and 2.39 [95% CI, 1.03–5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D–/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26–1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D–/R+ and were likely recipient KSHV reactivation or acquisition. Conclusions: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.

12 January 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
EAElizabeth C Arant
Elizabeth C Arant
TDThibaut Davy-Mendez
Thibaut Davy-Mendez
TLTao Liang
Tao Liang
MRMoreno Rodrigues
Moreno Rodrigues
CGCynthia Gay
Cynthia Gay
CDChristine M Durand
Christine M Durand
Background: Kidney transplantation (KT) from donors with human immunodeficiency virus (HIV-1) to recipients with HIV (HIV D+/R+) is noninferior to KT from donors without HIV (HIV D−/R+) with regard to safety. However, there may be differences in posttransplant infections. Methods: We performed a secondary analysis of the HOPE in Action KT Study (NCT02602262) comparing the time to first clinically relevant infection within 24 months posttransplantation in 99 HIV D+/R+ versus 99 HIV D−/R+. Secondary outcomes included incidence rates, infection-related death, and timing of clinically relevant infection, each stratified by donor HIV status. Results: The cumulative incidence of a clinically relevant infection at 24 months posttransplantation was 73.8% (95% confidence interval [CI]: 63.1%–81.2%) for HIV D+/R+ versus 64.7% (95% CI: 53.0%–73.4%) for HIV D−/R+. Comparing time to first clinically relevant infection in HIV D+/R+ versus HIV D−/R+, the adjusted hazard ratio (aHR) was 1.44 (95% CI: 1.01–2.04) at 24 months posttransplantation; for infections associated with hospitalization, the aHR was not significantly higher (1.21 [95% CI: .78–1.86). There were no significant differences in the number of infections, death from infection, duration, or site of infection between HIV D+/R+ versus HIV D−/R+, though viral infections were numerically more common in HIV D+/R+ (40% vs 35%). Conclusions: Although there was a statistically significant association between receipt of a kidney from a donor with HIV and time to first clinically relevant infection in the 24 months posttransplantation, there were no differences in infections associated with hospitalization. These data are overall reassuring as this emerging practice expands into clinical care. Clinical Trials Registration. NCT02602262.